Autoimmune & Rheumatology Clinical Trials Update: Week 44, 2026

Published October 30, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic Arthritis

This Phase 4 trial from Oslo University Hospital is exploring whether children and adolescents with inactive juvenile idiopathic arthritis (JIA) can safely stop taking TNF inhibitor monotherapy. The goal is to see if medication can be reduced without causing the disease to flare up, which could help lower side effects and improve quality of life. The study is recruiting in Norway and will monitor participants for 12 months to track any return of symptoms.

Safety of the Herpes Zoster Subunit Vaccine in Lupus

NYU Langone Health is conducting a Phase 4 trial to test the safety of the Herpes Zoster Subunit vaccine in adults with systemic lupus erythematosus (SLE). This study is important because it looks at whether the vaccine can prevent shingles without worsening lupus symptoms. People with different levels of lupus activity and treatment backgrounds are included, and the trial is recruiting across the United States.

Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis

This Phase 3 trial in Canada is testing low-dose aspirin as a way to prevent serious blood vessel problems in patients with giant cell arteritis (GCA). If aspirin proves effective, it could offer a simple and widely available option to reduce the risk of complications like strokes or heart attacks in this condition. The study plans to enroll 120 participants and is currently recruiting.

Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis

AbbVie is running this Phase 2b study to evaluate a new combination pill for adults with active rheumatoid arthritis that has not responded well to other treatments. By combining two drugs, the trial aims to find out if patients can get better symptom control with fewer side effects compared to taking either drug alone. The study is enrolling about 250 participants worldwide and includes a 24-week treatment period with an optional extension.

Immune-Mediated Pathophysiology And Clinical Triage Program

This Phase 2 trial in Canada is testing whether adding hydroxychloroquine to prednisone improves treatment for immune-related arthritis or joint pain caused by cancer therapies. Researchers hope this combination will be safer and more effective than prednisone alone, potentially reducing side effects. The study is recruiting 46 participants and will assess results after 12 weeks of treatment.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.